Anika Therapeutics/$ANIK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Anika Therapeutics
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Ticker
$ANIK
Sector
Primary listing
Employees
235
Headquarters
Website
ANIK Metrics
BasicAdvanced
$192M
-
-$0.76
0.30
-
Price and volume
Market cap
$192M
Beta
0.3
52-week high
$17.10
52-week low
$7.87
Average daily volume
164K
Financial strength
Current ratio
4.718
Quick ratio
3.705
Long term debt to equity
16.865
Total debt to equity
16.865
Profitability
EBITDA (TTM)
-5.471
Gross margin (TTM)
56.56%
Net profit margin (TTM)
-9.64%
Operating margin (TTM)
-9.80%
Effective tax rate (TTM)
-7.22%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
-3.51%
Return on equity (TTM)
-6.71%
Valuation
Price to revenue (TTM)
1.817
Price to book
1.38
Price to tangible book (TTM)
1.48
Price to free cash flow (TTM)
41.324
Free cash flow yield (TTM)
2.42%
Free cash flow per share (TTM)
0.346
Growth
Revenue change (TTM)
-5.91%
Earnings per share change (TTM)
-80.09%
3-year revenue growth (CAGR)
-0.30%
10-year revenue growth (CAGR)
1.95%
3-year earnings per share growth (CAGR)
-9.28%
10-year earnings per share growth (CAGR)
-9.23%
What the Analysts think about ANIK
Analyst ratings (Buy, Hold, Sell) for Anika Therapeutics stock.
ANIK Financial Performance
Revenues and expenses
ANIK Earnings Performance
Company profitability
ANIK News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Anika Therapeutics stock?
Anika Therapeutics (ANIK) has a market cap of $192M as of March 14, 2026.
What is the P/E ratio for Anika Therapeutics stock?
The price to earnings (P/E) ratio for Anika Therapeutics (ANIK) stock is 0 as of March 14, 2026.
Does Anika Therapeutics stock pay dividends?
No, Anika Therapeutics (ANIK) stock does not pay dividends to its shareholders as of March 14, 2026.
When is the next Anika Therapeutics dividend payment date?
Anika Therapeutics (ANIK) stock does not pay dividends to its shareholders.
What is the beta indicator for Anika Therapeutics?
Anika Therapeutics (ANIK) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.